Specific therapies for RTT, such as trofinetide, an analogue of the neuropeptide IGF-1 with anti-inflammatory properties, has successfully completed Phase III clinical trials (Neul et al., 2022) and is now approved by the FDA in the United States for the treatment of RTT (Harris, 2023). Here, IGF1 is linked to Rett syndrome.